Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type5 A4 p, d6 M6 y" R* q* E" Y
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
4 \1 B. @$ s- v+ Author Affiliations
3 r. j2 D0 y, I9 |$ \& T g. j) s$ X" B- \( U' d0 z
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
! S2 `- S) a8 r7 p1 V) _& q, k2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
/ D. _- F/ _2 F2 y) n3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
+ A( d8 K& k7 k- D0 m4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
. N& ?6 [! s5 M' U$ f5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 3 m$ _8 X8 a3 L$ B7 v" }$ h7 h e
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan , R" ?! X! Q& p
7Kinki University School of Medicine, Osaka 589-8511, Japan 8 d; t: t: ]9 p
8Izumi Municipal Hospital, Osaka 594-0071, Japan k# D+ p+ v9 C, k) g) m
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
& ^: ?! m2 L( T, ~2 X& j$ vCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 5 Q* t2 O( i5 `" S
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. : V P V+ U8 k$ p4 @: [# | l" \7 ~
6 r$ T7 `" C6 j7 m0 m& O7 _3 Z |